Reuters news agency reported on Tuesday that Ukraine received its first batch of 500,000 doses of the AstraZeneca COVID-19 vaccine on 23 February 2021, allowing it to launch its delayed vaccine roll-out, starting with front-line medical workers and soldiers.
The President of Ukraine, Volodymyr Zelenskiy, tweeted: "We will start vaccination ASAP. We need to fight COVID together."
Ukraine's Health Minister, Maksym Stepanov, stated on Facebook: "Now we are urgently clearing the cargo through customs and the vaccine will immediately go to the regions."
Reportedly, Ukraine has lagged behind its neighbours in securing vaccines for its 41 million people, asking EU member states for help while refusing to buy the Sputnik V COVID-19 vaccine from Russia.
Ukraine had planned to launch mass vaccinations in mid-February 2021 through the global COVAX programme for poorer countries but the government said the roll-out was postponed due to a delay in delivery.
The current AstraZeneca doses were produced by the Serum Institute of India, and Ukraine approved the vaccine this week.
The health ministry said it had agreed to buy a total of 17 million doses of Indian-made vaccines, including 15 million doses of the Novavax shot.
So far, Ukraine has registered over 1.3 million COVID-19 cases and 25,309 deaths.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV